Precision secondary prevention is replacing one-size-fits-all stroke care
Recurrent ischemic stroke remains a major global cause of disability and death even as acute stroke systems improve. The central shift described in this review is not simply therapeutic refinement; it is a change in logic. Secondary prevention is moving away from standardized regimens applied broadly across patients and toward treatment selected by stroke mechanism, vascular risk profile, and, in some cases, pharmacogenomics.
That shift matters because recurrent events are not biologically identical. A patient with atrial fibrillation, another with non-cardioembolic small-vessel disease, and a third with embolic stroke of undetermined source do not share the same dominant pathway of thrombosis, embolism, or arterial injury. Preventive therapy that is too generic risks undertreating the mechanism that actually drives recurrence. The review ties this change to recent AHA/ASA and ESO guideline updates and to landmark trials that have forced clinicians to think in narrower, more mechanistic terms.
ESUS has moved from empiric anticoagulation to etiologic workup
One of the clearest examples is embolic stroke of undetermined source (ESUS). Early enthusiasm for empiric anticoagulation in this group has given way to a more disciplined approach centered on finding the cause first. Advanced imaging and biomarker-driven evaluation now sit at the center of this strategy, because ESUS is a syndrome, not a single disease.
A single antithrombotic decision cannot solve a problem whose source may be occult atrial fibrillation, nonstenotic atherosclerosis, atrial cardiopathy, or another embolic substrate. The review positions this diagnostic effort as the foundation of precision medicine in stroke prevention. In practical terms, the management question has shifted from “Should every ESUS patient receive anticoagulation?” to “Which hidden mechanism is most likely in this person, and what therapy best matches it?”
NAVIGATE ESUS and RE-SPECT ESUS are central to that reappraisal. Their collective influence pushed the field away from routine anticoagulation in unselected ESUS populations and toward systematic etiologic investigation. The biological rationale is straightforward: anticoagulation helps when fibrin-rich emboli or atrial thrombus dominate, but it offers little advantage when the true lesion is atherosclerotic or lacunar.
Dual antiplatelet therapy now depends on timing, selection, and genotype
For non-cardioembolic stroke, dual antiplatelet therapy has become the clearest example of precision prevention. Its value depends on choosing the right patient, the right window, and the right drug combination. The review places special emphasis on timing and pharmacogenomic guidance rather than on a blanket recommendation for all survivors of ischemic stroke.
CHANCE-2 is a key trial in this framework because it informed the use of pharmacogenomic-guided therapy, particularly when clopidogrel responsiveness may be altered. In a patient whose platelet inhibition is blunted by inherited metabolic variation, standard therapy can look effective on paper while failing at the bedside. A genotype-informed approach attempts to close that gap by matching antiplatelet choice to predicted drug response.
INSPIRES adds another layer by reinforcing the importance of early treatment selection after the index event. In stroke prevention, the clock matters because thrombotic risk is front-loaded after an ischemic event. Early recurrence often reflects a temporary surge in platelet activation, endothelial disruption, and vulnerable plaque behavior. Short-term DAPT addresses that acute vulnerability, while prolonged or indiscriminate intensification can expose patients to bleeding without proportional ischemic benefit.
Atrial fibrillation and DOACs remain the clearest anticoagulation success story
The review treats direct oral anticoagulants as established standard therapy for atrial fibrillation-related stroke prevention. This remains the clearest area where mechanism and treatment align cleanly. Atrial fibrillation creates a thromboembolic milieu that anticoagulation directly interrupts, and DOACs now occupy that space as the principal preventive option.
The importance of this point is not limited to prescription choice. It reflects the broader principle that stroke prevention succeeds when the drug class tracks the dominant pathophysiology. In atrial fibrillation, the source of recurrence is not primarily platelet-driven atherothrombosis; it is atrial clot formation and embolization. DOACs address that process more directly than antiplatelet therapy does.
The review also notes that DOACs are being explored for broader vascular protection. Even there, the theme remains the same: the field is testing whether anticoagulation can benefit risk states beyond classic atrial fibrillation without paying an unacceptable bleeding penalty. The answer will depend on identifying which patients truly share a thromboembolic biology with known anticoagulation-responsive disease.
Lipid lowering is becoming earlier, lower, and more intensive
Secondary prevention is not only about antithrombotic therapy. The review describes lipid management as moving toward earlier treatment, lower LDL-C targets, and more intensive combination therapy. This reflects a view of atherosclerosis as an active and modifiable biological process rather than a static background condition.
Aggressive LDL-C lowering stabilizes plaque, reduces lipid burden, and lowers the chance that a vulnerable arterial lesion will rupture or embolize. In recurrent stroke prevention, that matters because vascular events frequently arise from ongoing plaque activity rather than from a single historical insult. Combination therapy becomes relevant when one agent does not achieve the necessary reduction on its own.
The shift toward more intensive lipid control is especially important in patients whose stroke mechanism involves extracranial or intracranial atherosclerosis. In those patients, prevention is not merely about stopping clots; it is about changing the arterial substrate that makes future clots more likely.
Genomics, metabolomics, and artificial intelligence are moving in faster than the clinic
The review closes by pointing toward emerging tools including metabolomics, genomics, and artificial intelligence. These technologies promise finer risk prediction and more individualized treatment selection, especially when conventional clinical features do not fully explain recurrence risk. In theory, they could identify residual vascular risk, hidden embolic sources, or treatment response patterns that routine assessment misses.
The translational gap remains the central obstacle. Research tools can stratify risk in sophisticated ways, but routine stroke care still has to operate in real clinics, with variable access to imaging, laboratory support, and longitudinal follow-up. Operationalizing precision medicine in secondary prevention therefore requires more than statistical prediction. It requires workflows that can convert etiologic diagnosis into timely therapy choices.
For now, the most durable lesson is that recurrent ischemic stroke prevention is becoming more specific, not more generalized. Anticoagulation, antiplatelet therapy, and lipid lowering each have a narrower and more defensible place when matched to the mechanism of recurrence. The remaining challenge is whether advanced biomarkers and machine-based prediction can move from promising research tools to everyday decisions without widening the gap between evidence and practice.